AbbVie is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter. AbbVie did not immediately respond to Reuters' request for a comment. In December, AbbVie announced back-to-back acquisitions - a $8.7 billion plan to buy Cerevel and its $10.1 billion deal for ImmunoGen, which was recently completed.
(Bloomberg) -- Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.Most Read from BloombergNvidia Surges After AI Boom Shows No Signs of Letting UpTech Up in Late Hours on Nvidia’s Bullish Outlook: Markets WrapBiden Touts $1.2 Billion in Student Loan Relief With Eye to 2024Your 401(k) Will Be Gone Within a DecadeChina Tig
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.